Comparative Pharmacology
Head-to-head clinical analysis: DESOXIMETASONE versus ELOCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOXIMETASONE versus ELOCON.
DESOXIMETASONE vs ELOCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Elocon (mometasone furoate) is a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It binds to the glucocorticoid receptor, leading to increased synthesis of lipocortins that inhibit phospholipase A2, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene formation. It also suppresses cytokine production and inflammatory cell migration.
Apply a thin film to affected skin areas twice daily.
Apply a thin film to affected skin area once daily. Use no more than 45 g per week.
None Documented
None Documented
Clinical Note
moderateDesoximetasone + Gatifloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Gatifloxacin."
Clinical Note
moderateDesoximetasone + Rosoxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Rosoxacin."
Clinical Note
moderateDesoximetasone + Levofloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Levofloxacin."
Clinical Note
moderateTerminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation.
Terminal elimination half-life approximately 5-7 hours after topical application. Systemic half-life is short, limiting systemic accumulation with topical use.
Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile.
Primarily hepatic metabolism; metabolites excreted renally and in feces. Approximately 60% of a topical dose is excreted in urine as metabolites, 30% in feces.
Category A/B
Category C
Topical Corticosteroid
Topical Corticosteroid
Desoximetasone + Trovafloxacin
"The risk or severity of adverse effects can be increased when Desoximetasone is combined with Trovafloxacin."